Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Scheiner

Showing results (131-140 of 203) with videos related to

Pageof 21
Sort By:
Therapeutic Advances in Medical Oncology|March 7, 2022
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experienceTiago de Castro, Leonie S Jochheim, Melanie Bathon, et al.
Cancers|December 23, 2020
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular CarcinomaStephan Spahn, Daniel Roessler, Radu Pompilia, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2020
Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver diseaseBenedikt Simbrunner, Alexander Stadlmann, Philipp Schwabl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2020
Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal HypertensionKatharina Wöran, Georg Semmler, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|December 3, 2024
Metabolomic profiles differentiate between porto-sinusoidal vascular disorder, cirrhosis, and healthy individualsGeorg Semmler, Oleksandr Petrenko, Juanjo Jose Lozano, et al.
Alimentary Pharmacology & Therapeutics|January 23, 2026
The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLDLorenz Balcar, Georg Semmler, Bernhard Scheiner, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 7, 2025
Non-Invasive Stratification of Portal Hypertension in Patients With BCR::ABL1-Negative Myeloproliferative NeoplasmsLorenz Balcar, Lina Degenfeld-Schonburg, Can Hopp, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 30, 2025
Diagnostic and Clinical Implications of High Spleen-To-Liver Stiffness Ratio in MASH-A Prospective, Comparative StudyChristian Sebesta, Mathias Jachs, Lukas Hartl, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2025
Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver DiseaseBenedikt Simbrunner, Ida Falk Villesen, Georg Semmler, et al.
Hepatology International|May 22, 2021
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomesLukas Hartl, Mathias Jachs, Christopher Desbalmes, et al.
Pageof 21

Showing results (131-140 of 203) with videos related to

Sort By:
Pageof 21
Therapeutic Advances in Medical Oncology|March 7, 2022
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experienceTiago de Castro, Leonie S Jochheim, Melanie Bathon, et al.
Cancers|December 23, 2020
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular CarcinomaStephan Spahn, Daniel Roessler, Radu Pompilia, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2020
Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver diseaseBenedikt Simbrunner, Alexander Stadlmann, Philipp Schwabl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2020
Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal HypertensionKatharina Wöran, Georg Semmler, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|December 3, 2024
Metabolomic profiles differentiate between porto-sinusoidal vascular disorder, cirrhosis, and healthy individualsGeorg Semmler, Oleksandr Petrenko, Juanjo Jose Lozano, et al.
Alimentary Pharmacology & Therapeutics|January 23, 2026
The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLDLorenz Balcar, Georg Semmler, Bernhard Scheiner, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 7, 2025
Non-Invasive Stratification of Portal Hypertension in Patients With BCR::ABL1-Negative Myeloproliferative NeoplasmsLorenz Balcar, Lina Degenfeld-Schonburg, Can Hopp, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 30, 2025
Diagnostic and Clinical Implications of High Spleen-To-Liver Stiffness Ratio in MASH-A Prospective, Comparative StudyChristian Sebesta, Mathias Jachs, Lukas Hartl, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2025
Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver DiseaseBenedikt Simbrunner, Ida Falk Villesen, Georg Semmler, et al.
Hepatology International|May 22, 2021
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomesLukas Hartl, Mathias Jachs, Christopher Desbalmes, et al.
Pageof 21